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Abstract
Summary Many patients at increased risk of fractures do not take their medication appropriately, resulting in a substantial decrease in
the benefits of drug therapy. Improving medication adherence is urgently needed but remains laborious, given the numerous and
multidimensional reasons for non-adherence, suggesting the need for measurement-guided, multifactorial and individualized solutions.
Introduction Poor adherence to medications is a major challenge in the treatment of osteoporosis. This paper aimed to provide an
overview of the consequences, determinants and potential solutions to poor adherence and persistence to osteoporosis medication.
Methods Aworking group was organized by the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis
and Musculoskeletal diseases (ESCEO) to review consequences, determinants and potential solutions to adherence and to make
recommendations for practice and further research. A systematic literature review and a face-to-face experts meeting were undertaken.
Results Medication non-adherence is associated with increased risk of fractures, leading to a substantial decrease in the clinical
and economic benefits of drug therapy. Reasons for non-adherence are numerous and multidimensional for each patient,
depending on the interplay of multiple factors, suggesting the need for multifactorial and individualized solutions. Few inter-
ventions have been shown to improve adherence or persistence to osteoporosis treatment. Promising actions include patient
education with counselling, adherence monitoring with feedback and dose simplification including flexible dosing regimen.
Recommendations for practice and further research were also provided. To adequately manage adherence, it is important to (1)
understand the problem (initiation, implementation and/or persistence), (2) to measure adherence and (3) to identify the reason of
non-adherence and fix it.
Conclusion These recommendations are intended for clinicians to manage adherence of their patients and to researchers and
policy makers to design, facilitate and appropriately use adherence interventions.
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Introduction
Poor or non-adherence to medication remains a major prob-
lem in most chronic diseases, including osteoporosis.
Effective and safe medications are available to reduce the risk
of fractures [1], but numerous patients do not initiate treatment
for osteoporosis or do not take it appropriately, resulting in a
substantial clinical and economic burden [2]. Initiation of
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osteoporosis therapy is even poorer than in other disease areas,
with a substantial decrease in bisphosphonates initiation ob-
served in the last few years in Europe and the USA [3, 4].
Investing in medication adherence could improve health out-
comes and health system efficiency [5].
Poor or non-adherence with osteoporosis medications is
not a new problem. Several studies have already assessed
the consequences and burden of non-adherence with osteopo-
rosis medications being one of the major challenges of suc-
cessful osteoporosis management [6] and have highlighted the
urgency of managing medication adherence. In 2012, a sys-
tematic review of interventions to improve adherence to oste-
oporosis medications suggested few high-quality studies and
mixed effects of interventions [7]. In recent years, osteoporo-
sis management has evolved (e.g. new treatments, new diag-
nostic tools, FLS organizations), more interventions to im-
prove adherence have been tested and a better understanding
of the determinants of non-adherence is available.
Considering the burden of non-adherence with osteoporo-
sis medications and the need to provide up-to-date recommen-
dations to manage medication adherence, a working group
was convened by the European Society on Clinical and
Economic Aspects of Osteoporosis, Osteoarthritis and
Musculoskeletal Diseases (ESCEO) to review the conse-
quences and determinants of poor adherence and interventions
to manage adherence and improve persistence to osteoporosis
medication. In addition, this paper aims to provide recommen-
dations for practice and for further research. Information in-
cluded in this review could be of value to help not only clini-
cians to manage adherence of their patients but also for re-
searchers and policy makers involved in osteoporosis.
Methods
An international working group was formed to review the
consequences and determinants of poor adherence and inter-
ventions, to manage adherence and improve persistence to
osteoporosis medication and to provide recommendations
for practice and for further research. The working group com-
prised clinical scientists, researchers (including experts in ad-
herence) and a patient selected by the Scientific Advisory
Board of ESCEO.
In preparation for a working group meeting, a systematic
literature review was conducted to identify articles about the
determinants and interventions to improve adherence or per-
sistence to osteoporosis medications. The literature search was
conducted for articles up to December 2018 in PubMed.
Further details about the search strategy and inclusion of arti-
cles can be found in Cornelissen et al. [8]
A face-to-face meeting then took place on 22 January
2019. The meeting started with three short presentations about
the clinical and economic consequences of non-adherence to
osteoporosis medications (JYR), the determinants of non-
adherence to osteoporosis medications (MH) and the potential
solutions to improve adherence to anti-osteoporosis medica-
tions (DC). A group discussion led byMH andADP followed.
Each participant had the opportunity to comment on the de-
terminants, consequences and potential solutions and then to
provide recommendations for practice and further research.
Following this meeting and a symposium that was held at
theWorld Congress of Osteoporosis (WCO-IOF-ESCEO con-
gress, 6 April 2019), members of the writing team (MH, DC,
BV, BA, JYR, JK, AG, PH) reviewed a first version of the
article drafted byMH; this was then reviewed and commented
on by all members of the working group.
Terminology
In the literature, a number of terms such as ‘adherence’, ‘com-
pliance’, ‘concordance’ and ‘persistence’ have been used to
define how patients take their medicines [9]. In 2012, a col-
laboration of European research groups in the field of medi-
cation adherence funded by the European Commission sug-
gested the ABC taxonomy for describing and defining adher-
ence to medications [9], which will be used in this paper.
Adherence to medication is defined as ‘the process by which
patients take their medications as prescribed, composed of A)
initiation, B) implementation and C) discontinuation’ [9, 10].
Initiation occurs when the patient takes the first dose of a
prescribed medication, discontinuation when the patient stops
taking the medication and implementation is the extent to
which a patient’s actual dosing corresponds to the prescribed
dosing regimen, from initiation until the last dose. Medication
persistence is further defined as the length of time between
initiation and the last dose, which immediately precedes dis-
continuation [9]. Overall, this definition is in agreement with
the definition of the Group for the Respect of Ethics
Excellence in Science in osteoporosis [11], with the exception
that implementation has replaced compliance, and initiation is
preferred over primary adherence.
Adherence to osteoporosis medications,
clinical and economic consequences
In a recent review including 124 studies, the prevalence of
medication adherence ranged from 12.9 to 95.4% [12].
Several studies have reported that initiation, implementation
and persistence to osteoporosis medications are suboptimal. In
line with treatment initiation rates in other diseases [13], about
20–30% of patients do not initiate a treatment after a prescrip-
tion for oral bisphosphonates [14]. In addition, patients on
bisphosphonates frequently miss doses and therefore do not
implement as prescribed [15]. Persistence rates at 1 year for
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oral bisphosphonates are commonly estimated between 16
and 60% [16–18], in line with a review of 95 clinical studies
from different disease areas suggesting that about 40% of
patients discontinued at 1 year [19]. For example, in a large
observational Belgian study, persistence rates to oral
bisphosphonates were estimated at 39.5% at 1 year, without
a gap of more of 5 weeks in treatment [20], while only 48% of
patients were adherent (defined as a medical possession ratio
(MPR) ≥ 80%). In another study, van Boven et al. showed that
persistence to weekly oral bisphosphonates was about 60% at
1 year and decreased to 25% at 5 years [21], in line with a
Danish study [22]. Other studies have even reported that less
than 20% were still on treatment as soon as after 12 months
after treatment initiation [23]. Differences in methodologies
(e.g. permissible gap to define persistence, adherence mea-
sures, incorporation of switchers) could explain the differ-
ences between studies and made direct comparison between
them difficult.
Further, osteoporosis remains largely underdiagnosed and
a substantial number of patients at increased risk of fractures
do not even receive any prescription for osteoporotic therapy
[24] or only calcium and vitamin D supplementation. The
osteoporosis treatment gap was estimated between 25 and
95% in European countries [25]. Even in randomised con-
trolled trials, persistence and adherence with therapy decline
over time, and any reduced effectiveness caused by subopti-
mal adherence is to some extent already captured in clinical
trials.
Different profiles of non-adherent patients could be identi-
fied [26]. Some patients never initiate a treatment, while
others delay initiation of therapy. There are patients who fre-
quently miss doses, and multiweek drug holiday periods have
also been observed. Several patients further discontinue treat-
ment earlier than prescribed. In a USA study, it was also ob-
served that among discontinuers, about 45% [27] reinitiated
therapy, with the majority doing so within 6 months of dis-
continuation, suggesting that many patients are thus exposed
to multiple episodes of starting and stopping of drug actions.
Finally, several medication switchers have been reported [28].
Failure to take account of switchers could distort estimates of
adherence and persistence.
Poor persistence and adherence to osteoporosis medica-
tions reduce the potential benefits of osteoporosis therapy,
lowering gains in bone mineral density and resulting in in-
creased risk of fragility fractures [29]. Two systematic reviews
and meta-analyses assessed the impact of adherence/
persistence to oral bisphosphonates on fracture risk. The
meta-analysis of Ross et al. [30] indicated that fracture risk
increased by approximately 30%with non-adherence (defined
as medical possession ratio < 80%) and by 30 to 40% with
non-persistence. Similarly, Imaz et al. [31] reported that low
adherence to oral bisphosphonates was significantly associat-
ed with increased non-vertebral fracture risk (relative risk
(RR) of 1.16), increased hip fracture risk (RR 1.28) and in-
creased vertebral fracture risk (RR 1.43).
Studies reporting adherence to osteoporosis medication
and its relationship with fracture risk mainly focused on oral
bisphosphonates, although data for other medications (e.g.
teriparatide, raloxifene, denosumab or zoledronic acid) also
revealed suboptimal levels [32, 33]. In a large US study, per-
sistence to teriparatide and denosumab at 1 year were estimat-
ed at 69% and 58% [34]. Non-persistence to denosumab could
further lead to important health problems as discontinuation
with denosumab has recently been shown to be associated
with rapid bone loss and increased risk of multiple vertebral
fractures [35]. Persistence to yearly intravenous injection of
zoledronic acid is also not convincing, as suggested by a study
that showed that only one-third of patients agreed to a second
administration after 1 year [36]. Furthermore, for some oste-
oporosis medications, persistence to generic formulations has
been shown to be poorer than for branded formulations [37,
38].
A few model-based studies have estimated the economic
consequences of non-adherence at a population level [2,
39–42], suggesting important clinical and/or economic impli-
cations of poor adherence/persistence with osteoporosis med-
ications. For example, poor adherence with osteoporosis med-
ications resulted in about 50% reduction in the potential ben-
efits observed in clinical trials (in terms of fractures prevented
and quality-adjusted life-years (QALY)) and a substantial de-
terioration of the cost-effectiveness resulting from these med-
ications [2, 40]. Medication adherence has further become an
important factor for inclusion in cost-effectiveness analyses in
osteoporosis [43–45]. Interestingly, economic studies have al-
so suggested that interventions to improve adherence may
likely confer cost-effectiveness benefits [43]. Improving ad-
herence to medication could lead to greater benefits that de-
signing a new more effective drug [46].
Determinants of non-adherence
Adherence is a complex multidimensional phenomenon deter-
mined by the interplay of several factors. Numerous determi-
nants of non-adherence have been identified in the literature
[12, 47]. The World Health Organization has classified these
factors into five main categories, i.e. patient-related, therapy-
related, condition-related, health system and socio-economic
factors [5]. Recently, Yeam et al. [12] conducted a systematic
literature review up to January 2018 to review and identify
factors that influence patients’ adherence to anti-osteoporotic
therapy. A total of 24 factors and 139 subfactors were identi-
fied from 124 relevant studies. The authors presented types
and number of studies that presented the case for and against
each specific factor and revealed that patient-related factors
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were the most commonly studied category followed by
therapy-related and condition-related category.
Condition-related factors that were associated with poorer
medication adherence included polypharmacy and having
gastro-intestinal diseases. History of falls, fractures and
screening for osteoporosis were however not associated with
higher adherence. This is important as patients with a recent
fracture are at imminent risk of a further fracture [48]. Patient-
related factors associated with poorer medication adherence
included male gender, lower education levels, misconceptions
about osteoporosis and lack of perceived benefits of therapy,
whereas higher age was associated with higher medication
adherence but only in half of the studies. Among therapy-
related factors, medication side effects, complex instructions
for medication administration and complex medication regi-
mens were associated with poorer adherence and lower dosing
frequency with higher adherence, while a history of anti-
osteoporosis treatment was not found to be a predictor of
adherence. Health system-based factors associated with
poorer medication adherence included care under different
medical specialties and lack of patient education (information
sharing, counselling from healthcare professional, etc.).
Socio-economic-related factors associated with poorer medi-
cation adherence included current smoking, lower income lev-
el and lack of medical insurance coverage [12].
This review did not classify the factors according to adher-
ence level, i.e. initiation, implementation and persistence. In
another review of systematic reviews that covered 19 disease
areas [47], a total of 771 individual factors of medication
adherence were identified of which most were determinants
of implementation, and only 47 determinants of persistence
with medication and no determinant were specifically provid-
ed for initiation. In the field of osteoporosis, the patient per-
ceived need for treatment, patient knowledge, bone density
testing, improved patient-provider relationship, hospitaliza-
tions and prescription use have been shown to be positively
associated with initiating osteoporotic therapy [49–52].
Reasons for not initiating osteoporotic therapy also include
lack of motivation, concern about side effects and medication
costs [52]. Reasons for poor implementation and persistence
with osteoporosis therapy include side effects of treatment,
difficulties with medication intake (e.g. 30 min before break-
fast), inconvenient dosing regimen, concern about treatment,
no perceived benefits, drug cost, misinformation, insufficient
motivation or dissatisfaction with their doctor visits [47,
53–55]. Adherence to osteoporosis medications is simply a
matter of patient choice, and is due mostly to deliberative
choice [56]. However, reasons for non-adherence can also be
unintentional, resulting from forgetfulness, especially in holi-
day period [53], and some irrational behaviour could also be
reported. Factors involved in treatment initiation may further
differ than factors involved in persistence or implementation.
As example, polypharmacy has been shown to have a positive
effect on treatment initiation with patients who have not pre-
viously taken medication being less likely to start [14] while
persistence and implementation are generally lower in patients
on multiple medications [12]. Lau et al. conducted focus
groups in Canada to understand reasons for non-adherence
and included different patients’ quotes regarding belief in the
importance of taking medications for osteoporosis,
medication-specific factors, beliefs regarding medications
and health, relationships with healthcare providers and infor-
mation exchange [57].
The patient participating at our working group stressed the
importance of giving a positive message to the patient and not
exaggerating the consequences if the patient does not take the
drug. Web and social media nowadays also attract a lot of
attention and could further negatively influence adherence to
treatment.
Reasons for non-adherence are therefore numerous and
multidimensional for the same patient. Each patient’s rea-
son(s) for non-adherence is different, depending on the inter-
play of these multiple factors, and could also change over time
and be different for each key element of adherence.
Medication adherence is therefore not predictable, suggesting
the need for individualized solutions.
Review of interventions
In 2012, Hiligsmann et al. [7] reviewed and critically appraised
interventions to improve adherence and persistence to osteo-
porosis medications. A total of 20 studies tested a patient ad-
herence intervention and reported quantitative results on ad-
herence. Education programs (e.g. written materials, counsel-
ling, motivational interviewing, combination) were the most
frequent intervention (n = 9). Although patient education im-
proved medication adherence in four studies, two large-scale
randomized studies reported no benefits [58, 59]. Monitoring/
supervision by bone mineral density or bone turnover markers
were not shown to be associated with improved adherence.
However, a positive message revealing a good bone turnover
marker response was associated with a significant improve-
ment in persistence [60]. Simplification of dosing regimens
(with and without patient support program), electronic pre-
scription and a pharmacist intervention was associated with
improved adherence but only in couple of studies.
For the purpose of this working group, the previous sys-
tematic review was updated. A description of the literature
search, data and critical appraisal can be found in the article
of Cornelissen et al. [8]. A total of 15 studies were identified
between June 2012 and December 2018. Very few high-
quality studies (such as RCTs) were identified, and interven-
tions were mainly single component intervention.
Interventions were classified as patient education and/or sup-
port (n = 9), monitoring and supervision (n = 2), flexible
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dosing regimen and patient support (n = 3) and interdisciplin-
ary collaboration (n = 1). In each subtype of interventions,
mixed results on adherence/persistence were found where
some studies were shown to be successful and others not
(see next section). Interventions which include counselling
with education and/or flexible dosing regimens seem to be
most effective, as well as interventions aiming on testing and
initiating medication.
Recommendations for practice
Many factors affect medication adherence. Single interven-
tions could work but certainly not for all patients. There is
not one single intervention to manage adherence. Some rec-
ommendations to improve adherence are made below.
It is of primary importance to emphasize the need for treat-
ment adherence and to talk about adherence with patients. To
adequately manage medication adherence, at least three stages
are recommended:
1. What is the adherence problem (initiation, implementa-
tion and/or persistence)? It is key to identify the ele-
ment(s) of non-adherence problem(s) that you want to
address with the patient(s).
2. How to measure adherence? Different methods are avail-
able to measure the elements of medication adherence.
Prescription refills and databases are appropriate methods
to measure initiation and discontinuation of therapy [61]
while electronic monitoring is the preferred method for
implementation, although could be difficult to set up in
real-life settings [61]. The use of self-reports or pill counts
could be alternative methods.
3. What is the reason and how to fix it? Given the numerous
potential factors for non-adherence, it is therefore impor-
tant to understand the reason(s) for non-adherence for
each patient and to find an adequate personalized solution.
These three steps are in line with the Six Sigma framework
to manage medication adherence developed by Vrijens et al.
[62]. This framework includes definition (robust taxonomy),
measure (operational definition and performance), analysis
(understand the cause), addressing the cause and implementing
solutions and measurement-guided adherence management.
In addition to the updated systematic review of adherence
interventions in osteoporosis, a comprehensive list of inter-
ventions is provided with evidence about their effectiveness
including systematic reviews of adherence interventions in
other diseases including depression, cardiovascular diseases
and hypercholesterolaemia [63–65] (Table 1). Patient educa-
tion and counselling, adherence monitoring with feedback and
dose simplification including flexible dosing regimen were
associated with higher adherence improvements. We however
acknowledge that the efficacy of these actions is still largely
unknown and current data could be controversial.
Patient education and counselling were shown to improve
post-fracture care and treatment initiation, with more contro-
versial results on medication adherence. As a prominent ex-
ample for post-fracture care, the PREVOST trial suggested
that repeated oral and written information about fragility frac-
tures and osteoporosis management by a case manager in-
creased treatment initiation (53% initiated post-fracture care
in the intervention compared to 33% in the control) [66]. In
another study [67], patient education and referral to endocri-
nologist by a nurse were shown to improve the initiation of
calcium and vitamin D, although up to 50% of patients with
osteoporosis did not complete follow-up visits and/or did not
adhere to treatment recommendations for osteoporosis.
Assigning a screening coordinator to identify, educate and
follow up with fragility fracture patients and inform their phy-
sicians of the need to evaluate bone health was also shown to
increase treatment initiation [68]. A systematic screening
using FRAX® was also shown to increase use of, and adher-
ence to anti-osteoporosis medications in the UK SCOOP Trial
[69]. In addition, an osteoporosis school program (i.e. four
classes of 8–12 participants over 4 weeks), peer-led commu-
nity education and mentorship program or patient education
program were associated with improved knowledge of osteo-
porosis and initiation of treatment [70]. In a large pragmatic
randomized controlled trial, however, telephonic motivational
interviewing intervention was not associated with significant
improvements in medication adherence [59].
Adherence monitoring with feedback was also associated
with improved adherence. Stuurman-Bieze et al. [71] showed
that a proactive pharmaceutical care including counselling at
baseline and at 2 weeks and an active monitoring and counsel-
ling every 3 months by pharmacists for patients who should
have redeemed a new prescription leads to improved adher-
ence. Ducomlombier et al. [72] further suggests that phone
calls by medical secretaries every 2 months to motivate pa-
tients to maintain good adherence to the treatment and to de-
tect any difficulties in adherence with the prescription using
non-incriminating questions were associated with improved
adherence.
Dose simplification including flexible dosing regimen was
associated with improved adherence. Offering patients a med-
ication with less strict administration instructions such as the
use of gastro-resistant risedronate tablets that could be taken
after breakfast was associated with improved persistence to
treatment [73]. Longer dosing regimen (such as 6-month sub-
cutaneous injection of denosumab or yearly intravenous injec-
tion of zoledronic acid) can also be interesting to improve ad-
herence, although adherence levels have also been disappoint-
ed and far from optimal (see previously). Finally, a flexible
dosing regimen (before breakfast; in-between meals; before
bedtime) was also shown to be associated with improved
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persistence, although there was no statistical difference in terms
of adherence [74].
Improving patient interaction and shared decision-making
can also lead to improve treatment initiation and potentially
improve adherence. Several guidelines and international
groups recommend that shared decision-making be part of
standard treatment. In shared decision-making, both parties
share information: the clinician offers options and describes
their risks and benefits, and the patient expresses his or her
preferences and values [75]. Each participant is thus armed
with a better understanding of the relevant factors and shares
responsibility in the decision about how to proceed [75].
Decision aids emphasize shared decision-making and include
several features to support individualized treatment discussions
like those needed for fracture prevention. Decision aids for a
range of conditions have been shown to decrease decisional
conflict, increase knowledge and (when probabilities are in-
cluded in the aid) improve the accuracy of risk perception
[76]. Some decision aids aiming to facilitate shared decision-
making in osteoporosis have been designed and shown to im-
prove the quality of clinical decisions about bisphosphonate
therapy and may have improved adherence [77–79].
Providing patients with good quality information about os-
teoporosis, their risk and treatment options is needed as a crucial
step to increase the diagnosis and treatment of osteoporosis.
The doctor is therefore a key actor to improve medication ad-
herence. As an educator and a partner in making treatment
decisions, the doctor should be familiar with the medical
evidence, able to discuss complex medical information in a
manner that is understood by the patient and appropriately con-
sider the patient’s expectations, beliefs and concerns [80, 81]. A
doctor should thus facilitate interaction with the patient and
him/her, understand the patient’s needs and investigate the type
of treatment appropriate for the patients (e.g. dosing regimen).
Recommendations for further research
Some areas where further research is needed were identified.
First, it is important to improve our understanding on what
osteoporotic patients want, need and prefer and to better under-
stand how and why patients will (not) be adherent. It is partic-
ularly important to understand the root causes for each aspect of
adherence, i.e. initiation, implementation and persistence.
Qualitative research is the best way to understand patients’
needs and reasons for non-adherence and should be a starting
point for designing appropriate interventions. Stated preference
methods could also be interesting to reveal patients’ preferences
and important treatment characteristics [82].
Second, register-based studies can be attractive to investi-
gate the importance of different factors and identify the stron-
gest and most prevalent risk factors for poor adherence as
targets for intervention. Big (pharmaco-epidemiologic) data
provide new opportunities to help understand the reasons of
medication non-adherence and may also prove helpful in
assessing the effects of new initiatives in the area.
Table 1 Evidence about the effectiveness of adherence-enhancing interventions
Intervention subclass OP studies Other conditions* Conclusion
Education and support
Patient education program 4 4 Mixed evidence of effectiveness
Patient counselling 1 10 Strong evidence of effectiveness
Patient education combined with counselling 11 15 Strong evidence of effectiveness
Provision of educational material 2 5 No evidence of effectiveness
Monitoring supervision
Non-adherence monitoring 1 2 Limited evidence of effectiveness
Adherence monitoring combined with counselling 5 10 Strong evidence of effectiveness
Drug regimen combined with counselling 1 1 Limited evidence of effectiveness
Reminders to take the medication 1 7 Strong evidence of effectiveness
Monitoring biomarkers 3 N/a No evidence of effectiveness
Dose regimen adjustment and simplification
Dose simplification including flexible dosing regimen 4 8 Strong evidence of effectiveness
Individual medication program 1 1 Limited evidence of effectiveness
Costs covered N/a 1 Limited evidence of effectiveness
Other subclasses
Combination of interventions mentioned above 3 2 Mixed evidence of effectiveness
Other interventions 4 9 Low evidence of effectiveness
N/a not applicable
*Restricted to depression, cardiovascular diseases and hypercholesterolaemia
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Third, with a better understanding of patients’ needs and
non-adherence factors, it would then be possible to design
interventions that fit patients’ needs and wishes on a person-
alized manner. It is indeed recommended to develop complex,
individualized and multifactorial interventions. There is not
one single intervention to manage adherence. Involving pa-
tients in the preparation, development and assessment of these
complex interventions would be crucial [83]. Further research
is also warranted on patient involvement in medication adher-
ence research and patient empowerment and its role in pro-
moting adherence. Complex interventions would thus need to
be tested in large scale randomized controlled trials.
Fourth, as the cost of an adherence intervention may be
high, it would also be important to identify patients that will
be receptive to interventions and spend our limited resources
on those patients. We further need patient outcome tools to
better understand the patient perspective and patient biases in
decision-making concerning osteoporosis therapies [84].
In addition, web-based applications could play a crucial
role in supporting patients to improve their adherence to med-
ication. Further research focusing on digital adherence inter-
ventions is necessary to determine their value and ideal ways
to improve osteoporosis medication adherence.
Other areas for further research include the need to ade-
quately communicate about osteoporosis, fracture risk and
osteoporosis treatment to patients; development of shared
decision-making; assessment of adherence-management mod-
el (such as the three-stage model proposed previously); inno-
vative methods for monitoring medication adherence; and
policy/healthcare systems initiatives to support adherence
interventions.
Conclusions
Osteoporosis represents a significant healthcare burden in
European countries which, due to increasing life expectancies,
is predicted to increase further in the future [24]. Despite the
increasing burden and the availability of effective treatments
in reducing the risk of fractures, most patients are not taking
their medication appropriately or do not even start an osteo-
porosis medication. Improving treatment initiation and adher-
ence to therapy is therefore urgently needed to leverage in full
the benefits of drug therapy.
Poor and non-adherence withmedication is commonwith a
treatment gap estimated between and 95% in European coun-
tries [25] and about half of the patients discontinuing therapy
within 1 year. Reasons for non-adherence are numerous, di-
verse and multidimensional, depending on the interplay of
multiple factors and may be different for each key element
of adherence. Few single interventions have been shown to
improve adherence or persistence to osteoporosis treatment.
Potentially, promising interventions include patient education
with counselling, adherence monitoring with feedback and
dose simplification including flexible dosing regimen.
Recommendations for practice and further research were pro-
vided, suggesting the need to emphasize the importance of
adherence to treatment and to talk about adherence with pa-
tients, and the need to implement sound measures of adher-
ence so that the intervention can be individualized. These
recommendations are intended for clinicians to manage adher-
ence of their patients and to researchers and policy makers to
design, facilitate and appropriately use adherence interven-
tions and to advance research in the field.
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